Increase in thyroglobulin antibody and thyroid peroxidase antibody levels, but not preterm birth-rate, in pregnant Danish women upon iodine fortification

Sofie Bliddal 1, Malene Boas 2, Linda Hilsted 3, Lennart Friis-Hansen 4, Anders Juul 2,5, Torben Larsen 6, Ann Tabor 5,7, Jens Faber 5,8, Dorthe Hansen Precht 9 and Ulla Feldt-Rasmussen 1,5

Departments of 1 Medical Endocrinology, Section 2132, 2 Growth and Reproduction, and 3 Clinical Biochemistry, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark, 4 Department of Clinical Biochemistry, Hilleroed Hospital, Hilleroed, Denmark, 5 Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, 6 Department of Foetal Medicine, Copenhagen University Hospital (Holbaek Hospital), Holbaek, Denmark, 7 Department of Obstetrics, Centre of Foetal Medicine, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark, 8 Department of Medicine O, Endocrine Unit, Copenhagen University Hospital (Herlev Hospital), Herlev, Denmark, and 9 Department of Child Psychiatry, Copenhagen University Hospital (Roskilde), Roskilde, Denmark

Abstract

Objective: The presence of thyroid antibodies in pregnancy has been associated with preterm birth. In the non-pregnant population, the implementation of the Danish iodine fortification program has increased the prevalence of thyroid antibodies. This study investigated the prevalence of thyroid peroxidase antibodies (TPOAbs) and thyroglobulin antibodies (TgAbs) in pregnant Danish women before, during and after implementation of the iodine fortification program and association with preterm birth.


Methods: In cohort 1 (n = 297), TPOAbs were measured (DYNOtest (BRAHMS)). In cohorts 2 (n = 148) and 3 (n = 923), both TPOAbs and TgAbs were measured (Kryptor immunofluorescent assay (BRAHMS)). The prevalence and effect of antibody positivity were explored using three cut-offs: TPOAbs and/or TgAbs >100 kU/L, TPOAbs and/or TgAbs >60 kU/L and TPOAbs >30 and/or TgAbs >20 kU/L. National preterm birth data were extracted from the National Birth Registry.

Results: In the three cohorts, TPOAb levels >60 kU/L were found in 5.4, 8.1 and 12.0% ($\chi^2(2, n = 1367) = 11.7, P = 0.003$) respectively, and TPOAbs and/or TgAbs >60 kU/L in 8.1 and 16.2% in cohorts 2 and 3 respectively ($\chi^2(2, n = 1070) = 6.5, P = 0.01$). TgAb levels (>20 kU/L) had increased plenty-fold from cohort 2 to 3 ($\chi^2(1, n = 1071) = 136.5, P < 0.001$). Preterm birth occurred in 4.1% of all pregnancies with no effect from antibody positivity (TPOAbs and/or TgAbs >60 kU/L, $\chi^2(1, n = 1039) = 0.0, P = 0.98$, aOR = 1.1, 95% CI (0.4–2.7)). The national preterm birth-rate showed no increase over the same period.

Conclusions: Thyroid antibody positivity in Danish pregnant women has more than doubled upon the implementation of the iodine fortification program without an increase in preterm birth-rate.
Introduction

Autoimmune thyroid disease in pregnancy has been associated with an increased risk of spontaneous abortion and preterm birth (1, 2). Even in euthyroid pregnant women, the presence of thyroid antibodies has been suggested to affect obstetrical outcome (3).

The mild-to-moderate iodine deficiency in the Danish population led to the implementation of a mandatory iodine fortification program of bread salt and household salt at a level of 13 ppm in 2000 (iodine fortification was officially recommended in 1998). This increased the median 24-h iodine excretion in urine in Eastern Denmark from 94 mg/day in 1998 to 140 mg/day in 2005 and 141 mg/day in 2008–2010 (4, 5). In the non-pregnant population, the implementation of the iodine fortification program has been shown to have increased the prevalence of thyroid autoimmunity (TPOAbs >30 U/mL) from 14.3 to 23.8% (P < 0.001) and TgAbs >20 U/mL from 13.7 to 19.9% (P < 0.001)) (6), even more so in women of reproductive age (TPOAbs >30 and/or TgAbs >20 U/mL from 19.1 to 33.5% (data provided by IB Pedersen (6)). Similar experiences have been reported from populations in Sri Lanka and Greece (7, 8). In animal studies, the association between thyroid autoimmunity and dietary iodine intake is well established; the pathogenesis is complex, but among other aspects, seems to be a chemokine upregulation attracting lymphocytes into the thyroid gland, which leads to thyroiditis (9).

Thyroid autoimmune disease generally improves in pregnancy due to the pregnancy-induced immune suppression (10, 11). On the other hand, pregnancy-related changes in the thyroid hormone homeostasis pose stress to the thyroid hormone production, which requires both a sufficient iodine intake and a well-functioning thyroid gland. Women with thyroid antibodies seem to have difficulties meeting the physiological demands of pregnancy and thus be at higher risk of thyroid failure at term (10). Although it is well established that overt thyroid disease poses a risk to both mother and child (12, 13), the a priori role of thyroid antibody presence is still uncertain. Data from the large Dutch Generation R study (14) found the effect of positive TPOAbs on risk of preterm birth to be insignificant in euthyroid women and in women with increased TSH, when adjusting for maternal comorbidities. Also, a prospective study by Mannistö et al. did not find an association between antibody positivity and preterm birth (15). However, meta-analyses (16, 17) have demonstrated a tendency towards a higher risk of preterm birth among thyroid antibody-positive women – although studies included in such analyses vary substantially in conclusions, publication year, assay methods and patient population (1). Studies investigating the impact of TgAb status on pregnant women are few, which recently prompted the American Thyroid Association to call for such studies (18).

We investigated the prevalence of TPOAbs and TgAbs in pregnant Danish women with no known thyroid disease before, during and after the implementation of the mandatory iodine fortification program, and investigated the association hereof with the risk of preterm births during the same period.

Subjects and methods

Subjects

The study was a comparative cohort study of 1745 Danish pregnant women attending routine prenatal care at a Copenhagen University Hospital, Copenhagen, Denmark. In three cohorts, data were collected before (1996–1998), during (2000–2003) and after (2008–2009) implementation of the iodine fortification program respectively. Cohort characteristics are illustrated in Fig. 1 and Table 1.

As previously described (19), cohort 1 consisted of 316 pregnant women attending prenatal care at the Copenhagen University Hospital (Rigshospitalet) between 1996 and 1998. The women were consecutively enrolled in a prospective longitudinal study of stress factors during pregnancy. Cohort 2 was gathered from 2000 to 2003 as part of a prospective longitudinal study regarding foetal growth during pregnancy, and 151 women referred to prenatal care at the Copenhagen University Hospital (Herlev) were consecutively included (19, 20). The third cohort consisted of 1278 blood samples drawn from women who participated in the first trimester risk assessment for Down’s syndrome at Copenhagen University Hospital (Rigshospitalet) in 2008 and their obstetric outcome data (21).

All three studies were approved by the regional ethics committee (reference numbers: cohort 1; 01-077/96, cohort 2; KF 01 276357 and cohort 3; H-1-2010-014).

Biochemistry

In cohort 1, the 1235 AutoDelfia automatic fluoroimmunoassay system (Wallac, Turku, Finland) was...
used to analyse the following: thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) (19). The same variables were analysed with the Roche Modular Analytics E170 electrochemiluminescence immunoassay (Roche Diagnostics GmbH) in cohorts 2 and 3 (19, 21). The interassay coefficients of variance in the three cohorts were for TSH in cohort 1, 4.8, 2.2 and 2.2% at the concentrations of 0.05, 0.9 and 17.6 U/L respectively, in cohort 2, 8.7 and 8.4% at concentrations of 0.9 and 4.9 U/L respectively, and in cohort 3, 7.2, 3.2 and 3.3% at concentrations of 0.04, 0.2 and 3.7 U/L respectively; for FT4 in cohort 1, 5.3, 3.7 and 3.1% for 9.3, 15.9 and 19.5 pmol/L respectively, in cohort 2, 6.0 and 8.1% at concentrations of 12 and 30 pmol/L respectively, and in cohort 3, 2.7, 2.6 and 3.6% at concentrations of 14.9, 17.5 and 35.9 pmol/L respectively; for FT3 in cohort 1, 10.7, 4.4, 3.2 and 1.6% at concentrations of 2.8, 4.7, 6.5 and 9.7 pmol/L respectively, in cohort 2, 6.4 and 6.4% at concentrations of 5.3 and 15.0 pmol/L respectively, and in cohort 3, 5.1, 2.5 and 3.7% at concentrations of 2.8, 5.9 and 15.5 pmol/L respectively.

In all three cohorts, thyroid antibodies had been analysed by use of BRAHMS assay; in cohort 1, the DYNOnet radioimmunoassay, and in cohorts 2 and 3, the automated Kryptor immunofluorescent assay. In cohorts 1, 2 and 3, the respective functional assay sensitivities for thyroid peroxidase antibodies (TPOAb) were 30, 28 and 50 kU/L, and for thyroglobulin antibodies (TgAb) (only measured in cohorts 2 and 3), 25 and 33 kU/L, respectively.

In all three cohorts, thyroid antibodies had been analysed by use of BRAHMS assay; in cohort 1, the DYNOnet radioimmunoassay, and in cohorts 2 and 3, the automated Kryptor immunofluorescent assay. In cohorts 1, 2 and 3, the respective functional assay sensitivities for thyroid peroxidase antibodies (TPOAb) were 30, 28 and 50 kU/L, and for thyroglobulin antibodies (TgAb) (only measured in cohorts 2 and 3), 25 and 33 kU/L, respectively. The same particular antibody assays have been compared and validated by Pedersen et al. (6) who established a cut-off for antibody positivity across methods of TPOAb

### Table 1  Characteristics of the three cohorts.

<table>
<thead>
<tr>
<th></th>
<th>Cohort 1 (n=297)</th>
<th>Cohort 2 (n=148)</th>
<th>Cohort 3 (n=923)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gestational age range at visit (weeks)</strong></td>
<td>14–22 (19)</td>
<td>4–41 (16)</td>
<td>6–20 (11)*</td>
</tr>
<tr>
<td><strong>Mean maternal age at visit (years)</strong></td>
<td>29.6 (3.7)</td>
<td>31.1 (4.7)</td>
<td>31.1 (4.3)*</td>
</tr>
<tr>
<td><strong>Mean BMI (kg/m²) (s.d.)</strong></td>
<td>22.0 (2.9)</td>
<td>24.0 (4.7)</td>
<td>22.7 (4.2)*</td>
</tr>
<tr>
<td><strong>Smoking, n (%)</strong></td>
<td>2 (0.7)</td>
<td>31 (20.9)</td>
<td>56 (6.1)*</td>
</tr>
<tr>
<td><strong>Pregnancy achieved by ART, n (%)</strong></td>
<td>10 (3.4)</td>
<td>4 (2.7)</td>
<td>73 (7.9)*</td>
</tr>
<tr>
<td><strong>Parity, mean (s.d.)</strong></td>
<td>1.4 (0.6)</td>
<td>1.8 (0.8)</td>
<td>1.5 (0.7)*</td>
</tr>
<tr>
<td><strong>Median TSH (U/L) (s.d.)</strong></td>
<td>1.4 (0.7)</td>
<td>1.5 (1.1)</td>
<td>1.4 (1.1)</td>
</tr>
</tbody>
</table>

*P < 0.05 by one-way ANOVA or chi-square as appropriate. **Test for significance performed on log transformed data.

ART, assisted reproductive technology; BMI, body mass index; s.d., standard deviation.
In cohorts 1 and 2, where multiple blood samples had been drawn from each woman, we included the first sample in which thyroid antibody levels had been analysed. We excluded all women with known thyroid disease and/or diabetes, women with no information on possible thyroid disease and/or diabetes, twin pregnancies and those for whom there was no information on antibody levels during their pregnancy (Fig. 1).

Statistics

We used one-way ANOVA and chi-square tests for trends and between-group differences regarding demographics, antibody levels and preterm births. To approach normal distribution TSH, FT3 and FT4 values were log transformed. To further evaluate the association between antibody positivity and cohort origin, we performed binary logistic regression analyses including as covariates: gestational age at visit, maternal age at visit, parity, pregnancy achieved by assisted reproductive technology (assisted reproductive technology = 1, spontaneous = 0) and smoking status (smoker = 1, non-smoker = 0). Missing values were not replaced by dummy variables or missing indicators. Women from cohort 1 were excluded from all analyses including TgAb positivity as only TPOAbs were measured in cohort 1.

Finally, the risk of preterm birth as predicted by antibody positivity was tested using a binary logistic regression model including as covariates: gestational age at visit, maternal age at visit, parity, smoking status, pre-pregnancy BMI and assisted reproductive technology. In analyses of the association between antibody positivity and risk of preterm delivery, data were analysed across cohorts to achieve sufficient power. Due to multiple comparisons, all results from tests of antibody positivity and cohort origin and preterm birth, respectively, were Bonferroni corrected and thus a P < 0.004 was considered to be significant (P < 0.05/12 = 0.004). Level of significance in other analyses (P < 0.05).

Sample size calculation using SAS Enterprise Guide 7.1 was performed with an expected skewed weight between cohorts (1:4) and an aim of detecting a 10% difference in antibody positivity with a power of 0.8 yielding a total sample size of 385.

The proportions of preterm births in Denmark from 1997 to 2009 were based upon publicly available numbers from the Danish Medical Birth Register (24). The IBM SPSS Statistics, version 20.0 was used for all statistics.

Results

A total of 1368 pregnant Danish women were included in outcome analyses (Fig. 1 illustrates the inclusion process). Characteristics of the women in each cohort are presented in Table 1. Each of the variables was included in the adjusted regression analyses, as significant differences were detected. Thus, women in cohort 1 were slightly younger and almost all non-smokers, women in cohort 2 had higher BMI, parity and TSH levels and women in cohort 3 were more likely to have achieved pregnancy by assisted reproductive technology and have had blood drawn at an earlier time in pregnancy (Table 1). The difference in TSH concentrations among cohorts lost significance (P=0.48), when adjusting for gestational age at time of blood sampling by linear regression.

Increase in thyroid antibodies

Antibody positivity showed vast differences in prevalence among cohorts and according to the 3 cut-off levels used as illustrated in Fig. 2A, B, C and D. Especially, when using the lowest cut-off (TPOAbs >30 kU/L and/or TgAbs >20 kU/L), antibody positivity was found in more than half of the women in cohort 3, displaying a five-fold increase in comparison to cohorts 1 and 2. Using this cut-off, the difference among the 3 cohorts remained significant (P<0.001) after adjustment for confounders including gestational age at the time of blood sampling (Table 2). The increased prevalence of antibody positivity from cohort 1 to 3, i.e. from before to during and after iodine fortification, was also evident at the two higher cut-off levels, although only significant in unadjusted analyses. Prevalence of TPOAbs >30 kU/L was comparable between cohort 3 and the non-pregnant reference population (6), whereas the prevalence of TgAbs >20 kU/L was markedly higher in cohort 3 than that in the latter (Fig. 2A, B, C, D and Table 2).

In cohorts 1 and 2, several antibody measurements were performed during pregnancy for each woman. One woman developed TPOAbs during the course of pregnancy.
The remaining 30 women who had TPOAbs >30kU/L at their first visit (gestational week range 6–21), had lower TPOAb levels by the end of their pregnancy, although only nine (30%) of these women normalised their TPOAb levels (<30kU/L). TgAbs were measured multiple times in nine women in cohort 2; three developed TgAbs >20kU/L during pregnancy, three turned TgAb negative between their first (gestational week range 6–10) and last visit (gestational week range 33–41), and three had lower TgAb levels at the last visit.

Higher maternal age was significantly associated with antibody positivity (TgAbs and TPOAbs >60kU/L: aOR: 1.1 (1.0–1.2), P=0.01, TgAb >60 aOR: 1.1 (1.0–1.1), P=0.04), however, not when applying Bonferroni correction (P>0.004).

Preterm birth and thyroid autoimmunity

In total, 55 (4.1%) children were born preterm: One child before 28 weeks of gestation, 14 children between 28 and 33 weeks of gestation and 40 between gestational weeks 33 and 37. Across cohorts, no significant association was found between antibody positivity and risk of preterm birth regardless of the cut-off used (Table 3). Only isolated TPOAb levels >30kU/L showed a borderline significant effect on risk of preterm birth, however, a protective one (P value (χ², two sided) =0.07, adjusted OR: 0.51 (95% CI: 0.22–1.17), P=0.11). Despite the lack of significance, there was a noteworthy higher upper limit of the 95% CI for the adjusted OR of TgAb positivity as a predictor of preterm birth compared to that of TPOAb positivity.

The proportion of preterm births within the cohorts were 3.1% in cohort 1, 6.1% in cohort 2 and 4.2% in cohort 3 with no significant between-cohort difference (χ²(2, n=1334) =2.10, P=0.35).
Table 2  Antibody-positivity according to cohort at different cut-offs. Proportion of antibody-positive women in each cohort according to different cut-offs for antibody-positivity. aOR of cohort origin adjusted for covariates: gestational age at blood sampling, maternal age at blood sampling, parity, pregnancy achieved by assisted reproductive technology, and smoking status.

<table>
<thead>
<tr>
<th>Antibody cut-off</th>
<th>Antibody</th>
<th>Cohort 1 (n = 297)</th>
<th>Cohort 2 (n = 148)</th>
<th>Cohort 3 (n = 923)</th>
<th>P-value (χ²)</th>
<th>P-value (aOR)</th>
<th>aOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPOAb &gt;30 kU/L</td>
<td>TPOAb</td>
<td>6.7</td>
<td>10.1</td>
<td>32.6</td>
<td>&lt;0.001*</td>
<td>0.000*</td>
<td>2.3 (1.5–3.4)</td>
</tr>
<tr>
<td>TgAb &gt;20 kU/L (%)</td>
<td>TgAb</td>
<td>–</td>
<td>4.7</td>
<td>56.4</td>
<td>&lt;0.001*</td>
<td>0.000*</td>
<td>4.3 (2.7–6.8)</td>
</tr>
<tr>
<td>TPOAb and/or TgAb</td>
<td>TPOAb and/or TgAb</td>
<td>–</td>
<td>10.1</td>
<td>62.6</td>
<td>&lt;0.001*</td>
<td>0.000*</td>
<td>3.7 (2.5–5.3)</td>
</tr>
<tr>
<td>TPOAb and TgAb</td>
<td>TPOAb and TgAb</td>
<td>–</td>
<td>4.7</td>
<td>27.5</td>
<td>&lt;0.001*</td>
<td>0.000*</td>
<td>2.3 (1.4–3.7)</td>
</tr>
</tbody>
</table>

>60 kU/L (%)  

<table>
<thead>
<tr>
<th>Antibody cut-off</th>
<th>Antibody</th>
<th>Cohort 1 (n = 297)</th>
<th>Cohort 2 (n = 148)</th>
<th>Cohort 3 (n = 923)</th>
<th>P-value (χ²)</th>
<th>P-value (aOR)</th>
<th>aOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPOAb</td>
<td>TPOAb</td>
<td>5.4</td>
<td>8.1</td>
<td>12.0</td>
<td>0.003*</td>
<td>0.20</td>
<td>1.3 (0.9–2.1)</td>
</tr>
<tr>
<td>TgAb</td>
<td>TgAb</td>
<td>–</td>
<td>2.0</td>
<td>9.3</td>
<td>0.001*</td>
<td>0.13</td>
<td>1.6 (0.9–3.0)</td>
</tr>
<tr>
<td>TPOAb and/or TgAb</td>
<td>TPOAb and/or TgAb</td>
<td>–</td>
<td>8.1</td>
<td>16.2</td>
<td>0.009</td>
<td>0.06</td>
<td>1.5 (1.0–2.3)</td>
</tr>
<tr>
<td>TPOAb and TgAb</td>
<td>TPOAb and TgAb</td>
<td>–</td>
<td>2.0</td>
<td>5.2</td>
<td>0.10</td>
<td>0.56</td>
<td>1.2 (0.6–2.3)</td>
</tr>
</tbody>
</table>

>100 kU/L (%)  

<table>
<thead>
<tr>
<th>Antibody cut-off</th>
<th>Antibody</th>
<th>Cohort 1 (n = 297)</th>
<th>Cohort 2 (n = 148)</th>
<th>Cohort 3 (n = 923)</th>
<th>P-value (χ²)</th>
<th>P-value (aOR)</th>
<th>aOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPOAb</td>
<td>TPOAb</td>
<td>4.7</td>
<td>7.4</td>
<td>8.1</td>
<td>0.14</td>
<td>0.88</td>
<td>1.0 (0.7–1.6)</td>
</tr>
<tr>
<td>TgAb</td>
<td>TgAb</td>
<td>–</td>
<td>1.4</td>
<td>5.0</td>
<td>0.05</td>
<td>0.64</td>
<td>1.2 (0.6–2.5)</td>
</tr>
<tr>
<td>TPOAb and/or TgAb</td>
<td>TPOAb and/or TgAb</td>
<td>–</td>
<td>7.4</td>
<td>10.1</td>
<td>0.31</td>
<td>0.53</td>
<td>1.2 (0.7–1.8)</td>
</tr>
</tbody>
</table>

Over a similar period as the span of the three cohorts, no increase was observed in the proportion of women who gave birth preterm at the Copenhagen University Hospital nor nationwide (Fig. 3) (24). The national average annual birth count from 1997 to 2009 was 63,477, of which an average of 3,779 (6.0%) was preterm births (24). In Fig. 3, the preterm birth rates at the Copenhagen University Hospital (Rigshospitalet only) from 1997 to 2009 included twin births and births after referrals of all extremely preterm labours in the region – in supplement to the births reported in cohort 1 (women attending prenatal care at the Copenhagen University Hospital (Rigshospitalet)) and cohort 3 (women attending the national Down’s screening program).

Discussion

The present study demonstrated a plenty-fold rise in the prevalence of positive thyroid antibody levels in Danish

Table 3  Risk of preterm birth according to antibody-positivity. Proportion of women giving birth preterm or at term, respectively, who were thyroid antibody-positive according to different cut-offs used.

<table>
<thead>
<tr>
<th>Obstetric outcome</th>
<th>Term (n = 1279)</th>
<th>Preterm (n = 55)</th>
<th>P-value (χ²)</th>
<th>P-value (aOR)</th>
<th>Adjusted OR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibody cut-off</td>
<td>TPOAb</td>
<td>25.2</td>
<td>14.5</td>
<td>0.07</td>
<td>0.11</td>
</tr>
<tr>
<td>TgAb &gt;20 kU/L (%)</td>
<td>TgAb</td>
<td>49.8</td>
<td>47.8</td>
<td>0.79</td>
<td>0.87</td>
</tr>
<tr>
<td>TPOAb and/or TgAb</td>
<td>TPOAb and/or TgAb</td>
<td>56.0</td>
<td>54.3</td>
<td>0.82</td>
<td>0.90</td>
</tr>
<tr>
<td>TPOAb and TgAb</td>
<td>TPOAb and TgAb</td>
<td>25.1</td>
<td>13.0</td>
<td>0.06</td>
<td>0.20</td>
</tr>
<tr>
<td>TPOAb</td>
<td>TPOAb</td>
<td>10.3</td>
<td>7.3</td>
<td>0.47</td>
<td>0.40</td>
</tr>
<tr>
<td>TgAb</td>
<td>TgAb</td>
<td>8.0</td>
<td>10.9</td>
<td>0.50</td>
<td>0.25</td>
</tr>
<tr>
<td>TPOAb and/or TgAb</td>
<td>TPOAb and/or TgAb</td>
<td>15.1</td>
<td>15.2</td>
<td>0.98</td>
<td>0.85</td>
</tr>
<tr>
<td>TPOAb and TgAb</td>
<td>TPOAb and TgAb</td>
<td>4.5</td>
<td>4.3</td>
<td>0.95</td>
<td>0.82</td>
</tr>
<tr>
<td>TPOAb</td>
<td>TPOAb</td>
<td>7.3</td>
<td>5.5</td>
<td>0.79**</td>
<td>0.47</td>
</tr>
<tr>
<td>TgAb</td>
<td>TgAb</td>
<td>4.1</td>
<td>6.5</td>
<td>0.44**</td>
<td>0.29</td>
</tr>
<tr>
<td>TPOAb and/or TgAb</td>
<td>TPOAb and/or TgAb</td>
<td>9.6</td>
<td>10.9</td>
<td>0.80**</td>
<td>0.76</td>
</tr>
<tr>
<td>TPOAb and TgAb</td>
<td>TPOAb and TgAb</td>
<td>2.5</td>
<td>2.2</td>
<td>1.00**</td>
<td>0.99</td>
</tr>
</tbody>
</table>

*OR compared to antibody-negative women adjusted for covariates: gestational age at blood sampling, maternal age at blood sampling, parity, pregnancy achieved by assisted reproductive technology, smoking status, and maternal pre-pregnancy body mass index. **Fisher’s exact test used due to low numbers of women.

aOR, adjusted odds ratio; TgAb, thyroglobulin-antibodies; TPOAb, thyroid peroxidase-antibodies.
pregnant women after the national iodine fortification. However, this rise was not followed by an increase in preterm birth-rate.

Overt autoimmune thyroid disease leads to an increased risk of adverse pregnancy outcomes (2, 12, 13). In the present study of women without known thyroid disease, we did not find an association between maternal antibody positivity and preterm birth regardless of the cut-off used to define antibody positivity. Although this finding could be due to a small number of preterm births in our cohorts, this finding was replicated in data from the National Danish Birth Registry (24).

The increase in thyroid antibodies from the first to the last cohort was remarkable. Although different study designs and maternal characteristics (i.e. higher maternal age, smoking status and gestational age at the time of blood sampling (10, 17, 27, 28)) could have affected the antibody prevalence in the present study, these factors were insignificant in adjusted regression analyses. Smoking has previously been shown to decrease thyroid antibody positivity, especially TgAb positivity, in larger population studies (29, 30, 31). In the present study, including smoking as a covariate in the regression models for impact of iodine fortification or preterm delivery did not alter any results – likely due to the small number of smoking women. As only two women in cohort 1 were smokers, we reran all regression analyses excluding smokers from all three cohorts, which did not alter any of the results. Also, as women were further along in cohort 1 than cohort 3, the decrease in thyroid autoimmune activity during pregnancy (10, 28) may already have had an effect upon thyroid antibody presence. However, in the present study, only eight of 30 (26.7%) TPOAb-positive women with multiple samples turned TPOAb negative at the very end of pregnancy. In accordance with this, the large USA-based FaSTER trial (32) showed that women who were antibody positive in the first trimester were likely to remain antibody positive in the second trimester. A similar result was found in a study by Pop et al. (33) in which 17 of 85 (20%) TPOAb-positive (range 36–1900 kU/L) women turned TPOAb negative (<30 kU/L) from week 12 to 24 of their pregnancy. Interestingly, Moreno-Reyes et al. (34) found the frequency of TgAb-positive (>115 kU/L) women to be significantly higher in early pregnancy, whereas the frequency of positive TPO-Ab (>34 kU/L) did not vary with gestational age. If the production of TgAbs is somehow more susceptible to the pregnancy-related immunosuppression, this could explain some of the large between-cohort difference in TgAb positivity compared to TPOAb positivity in our cohorts.

We compared our results to the nationwide Danthyr study (6) in which the same BRAHMS assays were used as in our cohorts and interassay coefficients of variance validated. Further, another study found the involved TgAb assays to be interchangeable, despite some quantitative disagreement (35). Although some influence

isolated TgAbs in 5% of the women with a significant impact on TSH levels compared to that in controls – no impact on TSH was found in women with isolated TPOAb positivity (4%). This might suggest a need for distinction between different thyroid antibody types when investigating the impact on obstetric outcome.

Figure 3
Development in preterm birth rate at the Copenhagen University Hospital, in the region, and nationwide from 1997 to 2009 based on data from the National Danish Birth Registry (24).
by the methods used cannot be eliminated, it is unlikely to be the explanation for the multifold increase in the prevalence of positive antibodies over time. Our results were in accordance with studies from the non-pregnant Danish population (6, 36) and also with results found in Sri Lanka (37) and Poland (38), where the prevalence of TgAb-positive women has risen after increasing iodine exposure. In a study from 1989, Feldt-Rasmussen et al. (39) showed a prevalence of TgAbs and/or microsomal antibodies of 10% using a cut-off of 100 U/L. This is similar to the prevalence in the present study’s cohorts 2 and 3, thus substantiating the finding that the rise in autoantibody positivity after the iodine fortification is perhaps limited to low levels of thyroid antibody titres. Although interesting in light of the iodine fortification program, it is uncertain whether the higher prevalence of pregnant women with low, but positive, levels of TgAbs could have a pregnancy-related clinical significance (25, 40). In the thorough meta-analysis by He et al. (16), the studies defining antibody positivity at the highest titres did display a higher relative risk of preterm birth in antibody-positive women. This could support the hypothesis that preterm birth is caused by a global inflammatory state rather than thyroid function alteration, thus assuming thyroid antibody presence to be an epiphenomenon representing a general autoreactivity in the pregnant woman. A rejection of the foetus is thus to be considered equivalent to a ‘graft-vs-host’ reaction (28). In accordance with this, Oztas et al. (41) recently showed a significant association between first trimester IL-6 levels and adverse pregnancy outcomes including preterm birth – both in thyroid antibody-positive women and healthy controls.

The emerging studies on other risks related to thyroid antibody positivity in pregnant women, e.g. neurocognitive deficits in offspring (42, 43), serve as a reminder of the need for randomised controlled trials both with regard to screening strategies and treatment options (i.e. levothyroxine) (2, 44). A recent prospective randomised controlled trial published by Negro et al. (45) did not find a reduced miscarriage rate in TPOAb-positive women treated with levothyroxine. On the other hand, levothyroxine treatment reduced preterm birth rate in a randomized controlled trial by Nazarpour et al. (46). The present authors therefore strongly urge a cautious and evidence-based approach to treatment of euthyroid antibody-positive pregnant women with levothyroxine. In our population, such treatment regulations would mean medicating a minimum of 16% of all previously thyroid-healthy pregnant women, at high psychological and socioeconomic consequences.

**Conclusion**

This study investigated the prevalence of thyroid antibodies in pregnant women before and after the establishment of the mandatory Danish iodine fortification program. We found a plentiful increase in thyroid antibody-positive women over a period of 10 years, especially in the lowest level of TgAb positivity (Fig. 2). Regardless of the cut-off used, there was no association to preterm birth rate Table 3. To minimise the risk of bias due to cohort differences or lack of power, we compared our results to national data with which it corresponded: Data from the national Dantthy studies, which on the one hand showed an increased prevalence of thyroid autoimmunity (especially TgAb presence), and data from the Danish Medical Birth Registry of approximately 60 000 births per year, which on the other hand did not show an increase in the proportion of preterm births in Eastern Denmark during the same period (Fig. 3).

This study has given a unique historical insight into the consequences of iodine implementation to the thyroid autoimmune status of pregnant women. Further studies in pregnant women can provide a much needed clarification of the impact of maternal TPOAb and TgAb presence on foetal and obstetric outcomes.

**Declaration of interest**

S Bliddal and U Feldt-Rasmussen received an author honorarium from Merck-Serono for a publication in Thyroid International entitled ‘TPOAbs as a risk factor in pregnancy’. The research salary of U Feldt-Rasmussen was funded by an unrestricted grant from the Novo Nordic Foundation. The funding sources had no influence on the study designs and conduct hereof, or on the preparation of the present manuscript.

**Funding**

The work related to the studies and preparation of this article was most kindly supported by the Musikforlæggerne Agnes og Knut Mørks Foundation (2000, 2010, 2012, 2013, 2015); the Axel Muusfeldts Foundation (2010, 2013), the Danish Council for Independent Research: Medical Sciences (1994, 1997, 2010); the Ministry of Social Affairs (1995); the Videnskabsminister Erna Hamilton Foundation (2012); the Director Ib Henriksen Foundation (1996, 2012); the Snedkermester Sophus Jacobsen og hustru Astrid Jacobsens Foundation (2013); The Faculty of Medical Science’s Foundation (2013); the A P Møller Foundation for the Advancement of Medical Science (2000, 2001, 2012, 2013); the Frimodt-Heineke Foundation (2012); the Torben and Alice Frimods Foundation (2012); the Familien Hede Nielsens Foundation (2012); the Augustinus Foundation (2000); The Danish Medical Association’s Foundation (2002); Doctor Søren Segel and Johanne Wilbroe Segel’s Foundation (2002); illum Foundation (1997); the Arvid Nilsson Foundation (2011); the Gangsted Foundation (1995); Helsemonden (1999); the Elass Foundation (2001); The Faculty of Medical Science’s Foundation (2013), and the Copenhagen University Foundation (2013).

**Author contribution statement**

Dorthe Precht was in charge of the study design, clinical examinations, biochemical analyses (except TPOAbs) and data gathering in cohort
Acknowledgements
The authors appreciate the enthusiastic work of Inger Wüttjen and Brian Meilgren (Copenhagen University Hospital) who assisted in bioanalytical analyses, Lene Fris-Eskildsen (Copenhagen University Hospital) who assisted in gathering the cohort 1 data and Oriana Aragon (Yale University) who assisted in the preliminary statistical analyses.

References


---

Received 1 December 2016
Revised version received 6 February 2017
Accepted 17 February 2017